Search
etoricoxib (Arcoxia)
In pipeline. Mid 2002; as of 2011, still not FDA-approved.
Adverse effects:
1) long-term risk for adverse cardiovascular events similar to diclofenac [3]
2) edema, heart failure, hypertension more common with etoricoxib than diclofenac
3) adverse gastrointestinal events less common with etoricoxib than diclofenac (no differences in serious complications) [4]
Interactions
drug interactions
drug adverse effects (more general classes)
monitor with non steroidal anti-inflammatory agents (NSIADs)
General
cyclooxygenase-2 (COX-2) specific inhibitor
Properties
INHIBITS: cyclooxygenase-2
Database Correlations
PUBCHEM cid=123619
References
- Prescriber's Letter 8(11):61 2001
- Prescriber's Letter 12(3): 2005
COX-2 Inhibitor Safety: An Update
Detail-Document#: 210301
(subscription needed) http://www.prescribersletter.com
- Cannon CP et al, for MEDAL Steering Committee
Cardiovascular outcomes with etoricoxib and diclofenac in
patients with osteoarthritis and rheumatoid arthritis in the
Multinational Etoricoxib and Diclofenac Arthrities Long-term
(MEDAL) programme: A randomised aomparison.
Lancet 2006, 368:1771
PMID: 17113426
- Garcia Rodriguez LA and Patrignani P
The ever growing story of cyco-oxygenase inhibition.
Lancet 2006, 368:1745
PMID: 17113403
- Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP; MEDAL
Steering Committee.
Assessment of upper gastrointestinal safety of etoricoxib
and diclofenac in patients with osteoarthritis and rheumatoid
arthritis in the Multinational Etoricoxib and Diclofenac
Arthritis Long-term (MEDAL) programme: a randomised comparison.
Lancet. 2007 Feb 10;369(9560):465-73.
PMID: 17292766
- Drenth JP, Verheugt FW.
Do COX-2 inhibitors give enough gastrointestinal protection?
Lancet. 2007 Feb 10;369(9560):439-40. No abstract available.
PMID: 17292743